GERN - Geron Corporation Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

GERN

GERON CORPORATION

NASDAQ

$1.21

▲ UP 0.83% (0.01)

KEY STATISTICS

Market Cap$785.86 M

52w High$2.01

52w Low$1.04

Dividend Yield—

Frequency—

P/E-13.44

Volume6.37M

Shares Out.641.52M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Harout Semerjian

COMPENSATION 2026

Salary$318,190

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$40,258

Total$522,122

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 31, 1996

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

258

PRICE TARGET

Target High$8.00

Target Low$4.00

Target Median$6.00

Target Consensus$5.89

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$60.70M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2014-07-22	Forward	529:500

ETFS HOLDING THIS STOCK

ETFS HOLDING

125

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

52.01%

HOLDERS

374

TOP 8 OF 374 · RANKED BY POSITION SIZE

Ra Capital Management, L.P.

Soleus Capital Management, L.P.

41.5M sh

$61.85M

Deep Track Capital, LP

PRICE

$1.21 ▲ UP 0.83% (+$0.01)

OVERLAYS

About Geron Corporation

https://www.geron.com ↗

Geron Corporation is a late-stage biopharmaceutical company developing imetelstat, a telomerase inhibitor in Phase 3 trials for treating myeloid hematologic malignancies like myelodysplastic syndromes and myelofibrosis.

INDUSTRY

Biotechnology

A PRODUCT GERON CORPORATION IS KNOWN FOR

RYTELO (imetelstat)

RYTELO, Geron's first FDA-approved telomerase inhibitor for transfusion-dependent lower-risk MDS, is their flagship product marking a milestone in hematologic malignancy treatment.

COMPETITORS

COMPETITOR

Geron in 2025

SENTIMENT: + POSITIVE

EARNINGS · AUGUST 2025

Geron Corporation's Stock Surges Following Impressive Q2 Earnings and New CEO Appointment

In August 2025, Geron Corporation announced a significant 24% quarterly increase in net revenues to $49 million, largely driven by its key drug, RYTELO. This strong financial performance, which surpassed market expectations, was coupled with the appointment of Harout Semerjian as the new CEO, signaling a new phase of growth and strategic focus for the company.

RESTRUCTURING · DECEMBER 2025 · IN PROGRESS

Geron Corporation Announces Strategic Restructuring with a One-Third Workforce Reduction to Enhance Financial Discipline and Focus on RYTELO® Commercialization

In a decisive move to improve its financial discipline and long-term value, Geron Corporation initiated a strategic restructuring plan that includes reducing its workforce by approximately one-third. This decision, driven by the new CEO Harout Semerjian, is intended to streamline the organization and prioritize the commercial growth of its key product, RYTELO®, as well as advance its clinical trials.